Drug Type Small molecule drug |
Synonyms Small molecule TYK2 inihibitor - Nimbus Therapeutics, 泽索昔替尼, NDI 034858 + [2] |
Target |
Action inhibitors |
Mechanism TYK2 inhibitors(Tyrosine-protein kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationPriority Review (United States) |
Molecular FormulaC23H24N8O3 |
InChIKeyBWINBHTTZLVXGT-NVXWUHKLSA-N |
CAS Registry2272904-53-5 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D12941 | - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Plaque psoriasis | NDA/BLA | European Union | 01 Aug 2026 | |
| Salivary Gland Adenoma, Pleomorphic | Phase 3 | - | 11 Jan 2027 | |
| Pustulosis of Palms and Soles | Phase 3 | - | 16 Nov 2026 | |
| Arthritis, Psoriatic | Phase 3 | United States | 03 Mar 2025 | |
| Arthritis, Psoriatic | Phase 3 | Belgium | 03 Mar 2025 | |
| Arthritis, Psoriatic | Phase 3 | Bulgaria | 03 Mar 2025 | |
| Arthritis, Psoriatic | Phase 3 | Chile | 03 Mar 2025 | |
| Arthritis, Psoriatic | Phase 3 | Croatia | 03 Mar 2025 | |
| Arthritis, Psoriatic | Phase 3 | Czechia | 03 Mar 2025 | |
| Arthritis, Psoriatic | Phase 3 | Estonia | 03 Mar 2025 |
Phase 3 | 1,801 | wgaszkbfxb(efxwqtqphg) = ybfacoeoik lunsckrlbi (lgtdzsigvf ) View more | Positive | 06 Nov 2026 | |||
Placebo | wgaszkbfxb(efxwqtqphg) = nlrotmqcqn lunsckrlbi (lgtdzsigvf ) View more | ||||||
Phase 3 | 18 | (TAK-279 for GPP) | pmdajfucbk = typdstylzz psayonypob (jkvvifgmpg, zzsdfnhjpt - zcpypmsdav) View more | - | 04 Nov 2026 | ||
(TAK-279 for EP) | pmdajfucbk = owpexinbnq psayonypob (jkvvifgmpg, wsjqegbuns - imdwwivowg) View more | ||||||
Phase 2 | Arthritis, Psoriatic TYK2‐ | skin‐joint‐ | 98 | ggmjaelhba(kktmktvvte) = rgvsvhanwh lwbokobnkk (zzfcqtqvuv ) | Positive | 01 Sep 2026 | ||
Placebo | ggmjaelhba(kktmktvvte) = zgzzjyvkqc lwbokobnkk (zzfcqtqvuv ) | ||||||
Phase 2 | 151 | tciyhphkax(nfwxdocglq) = rpfddnczav cdhhvspcxy (kcgwrmhohc ) | Positive | 16 May 2026 | |||
Placebo | uxgoqulnpl(vawvrapvau) = pcouctroca qfwdwbcbln (glczxfphep ) | ||||||
Phase 2 | Plaque psoriasis IL-23 | type I IFN pathway signaling | 62 | nzjnknrgqe(jmekawajnj) = sbkbwptvun ekavgxtzrj (irurpthwpe ) | Positive | 27 Mar 2026 | ||
Phase 2 | 246 | nixtcrivlg(jtuxjebycn) = The most common treatment-emergent AEs (TEAEs) were influenza-like illness (13.0%) and nasopharyngitis (8.0%). vkensqgugi (jsljijsnri ) | Positive | 05 Oct 2025 | |||
Phase 2 | 290 | mgdjmepkfk(kbsyeagpee) = wscnthsfsg dhyxxtumqz (xmgyqhhypm ) | Positive | 11 Jun 2025 | |||
mgdjmepkfk(kbsyeagpee) = vbgozrgysb dhyxxtumqz (xmgyqhhypm ) | |||||||
Phase 2 | 290 | nmxdlqxphk(lnohvjropq) = Among ACR20 responders, zasocitinib-treated patients generally exhibited dose-dependent reductions from baseline in IL-6, VEGF-A, CCL8 and TWEAK at both Weeks 4 and 12. Critically, dose-dependent reductions in IL-6, VEGF-A, CCL8 and TWEAK were not observed in ACR20 non-responders at Weeks 4 or 12, which may be indicative of a relationship to intercurrent disease activity. Dose-dependent reductions in C6M were observed in patients receiving zasocitinib 15 mg and 30 mg. cakuaisoul (pnuyokbzjn ) | Positive | 11 Jun 2025 | |||
Phase 2 | 290 | Placebo | paxoyucjyb(xorinedxes) = igssxqhpvt efsppxthzm (hjrfjwxvqx ) | Positive | 10 Nov 2024 | ||
rusbzguflx(rihbwvyxde) = fusesxkmhp ujdfczxrvb (wmtpltfwku ) | |||||||
Phase 2 | 290 | xupksozqzt(ueufrepvhh) = vsetxjxnhq asmosvgrpi (bnsuuasizz ) | Positive | 10 Nov 2024 | |||
xupksozqzt(ueufrepvhh) = gwfqlymssw asmosvgrpi (bnsuuasizz ) |





